KR960015036B1 - C_17-20 리아제 억제제로서 유용한 17β-(사이클로 프로필옥시) 안드로스트-5-엔-3β-올 및 이와 관련된 화합물 - Google Patents

C_17-20 리아제 억제제로서 유용한 17β-(사이클로 프로필옥시) 안드로스트-5-엔-3β-올 및 이와 관련된 화합물 Download PDF

Info

Publication number
KR960015036B1
KR960015036B1 KR1019880004519A KR880004519A KR960015036B1 KR 960015036 B1 KR960015036 B1 KR 960015036B1 KR 1019880004519 A KR1019880004519 A KR 1019880004519A KR 880004519 A KR880004519 A KR 880004519A KR 960015036 B1 KR960015036 B1 KR 960015036B1
Authority
KR
South Korea
Prior art keywords
androst
ene
cyclopropyloxy
compound
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019880004519A
Other languages
English (en)
Korean (ko)
Other versions
KR880012634A (ko
Inventor
알. 앤젤라스트로 마이클
알. 블롬 토마스
Original Assignee
메렐 다우 파마슈티칼즈 인코포레이티드
게리 디. 스트리트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메렐 다우 파마슈티칼즈 인코포레이티드, 게리 디. 스트리트 filed Critical 메렐 다우 파마슈티칼즈 인코포레이티드
Publication of KR880012634A publication Critical patent/KR880012634A/ko
Application granted granted Critical
Publication of KR960015036B1 publication Critical patent/KR960015036B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1019880004519A 1987-04-22 1988-04-21 C_17-20 리아제 억제제로서 유용한 17β-(사이클로 프로필옥시) 안드로스트-5-엔-3β-올 및 이와 관련된 화합물 Expired - Fee Related KR960015036B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US041,170 1987-04-22
US07/041,170 US4891367A (en) 1987-04-22 1987-04-22 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Publications (2)

Publication Number Publication Date
KR880012634A KR880012634A (ko) 1988-11-28
KR960015036B1 true KR960015036B1 (ko) 1996-10-24

Family

ID=21915121

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004519A Expired - Fee Related KR960015036B1 (ko) 1987-04-22 1988-04-21 C_17-20 리아제 억제제로서 유용한 17β-(사이클로 프로필옥시) 안드로스트-5-엔-3β-올 및 이와 관련된 화합물

Country Status (20)

Country Link
US (1) US4891367A (enExample)
EP (1) EP0291717B1 (enExample)
JP (1) JP2593685B2 (enExample)
KR (1) KR960015036B1 (enExample)
CN (1) CN1024279C (enExample)
AT (1) ATE78487T1 (enExample)
AU (1) AU605575B2 (enExample)
CA (1) CA1309088C (enExample)
DE (1) DE3872938T2 (enExample)
DK (1) DK167766B1 (enExample)
ES (1) ES2051787T3 (enExample)
FI (1) FI87791C (enExample)
GR (1) GR3005370T3 (enExample)
HU (1) HU198508B (enExample)
IL (1) IL86140A (enExample)
NO (1) NO168892C (enExample)
NZ (1) NZ224287A (enExample)
PH (1) PH23863A (enExample)
PT (1) PT87293B (enExample)
ZA (1) ZA882715B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1326234C (en) * 1987-04-22 1994-01-18 Michael R. Angelastro 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966897A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5102915A (en) * 1990-03-22 1992-04-07 Merrell Dow Pharmaceuticals Inc. Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5051534A (en) * 1990-03-22 1991-09-24 Merrell Dow Pharmaceuticals Inc. Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
US5661141A (en) * 1995-03-27 1997-08-26 Petrow; Vladimir 19-oxygenated steroids as therapeutic agents
US6365597B1 (en) 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
WO2003039250A2 (en) * 2001-11-08 2003-05-15 Colorado State University Research Foundation Termite feeding stimulant and method for using same
WO2008157460A1 (en) 2007-06-15 2008-12-24 Cook, Kevin, M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135744A (en) * 1961-04-12 1964-06-02 Vismara Francesco Spa Cycloalkenyl ethers of 17 beta-hydroxy androstanes
CH471103A (de) * 1962-02-28 1969-04-15 Warner Lambert Pharmaceutical Verfahren zur Herstellung neuer (1'-Alkoxy)-alkyl- und cycloalkyläther von 17B-Hydroxysteroiden
US3475464A (en) * 1966-11-07 1969-10-28 Syntex Corp Process for the preparation of steroids and novel intermediates thereof
US3732209A (en) * 1971-03-15 1973-05-08 Hoffmann La Roche Novel 17beta-oxygenated cyclopropa(16alpha,17alpha)steroids
US3763146A (en) * 1972-02-03 1973-10-02 Syntex Corp Novel 17beta(tetrahydropyran-4-yloxy)steroids
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4361559A (en) * 1981-08-20 1982-11-30 E. R. Squibb & Sons, Inc. Antiinflammatory 17,17-bis (substituted thio) androstenes
US4420428A (en) * 1982-12-27 1983-12-13 E. R. Squibb & Sons, Inc. 16-Ketoandrostene-17-dithioketals
US4427592A (en) * 1983-01-31 1984-01-24 E. R. Squibb & Sons, Inc. Androstene-17-dithioketals
US4529548A (en) * 1984-05-07 1985-07-16 E. R. Squibb & Sons, Inc. 17β-(substituted thio)androstenes
CA1326234C (en) * 1987-04-22 1994-01-18 Michael R. Angelastro 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors

Also Published As

Publication number Publication date
ES2051787T3 (es) 1994-07-01
PT87293A (pt) 1988-05-01
NO168892B (no) 1992-01-06
NZ224287A (en) 1989-11-28
CN88102175A (zh) 1988-11-16
JP2593685B2 (ja) 1997-03-26
DK217488A (da) 1988-10-23
NO168892C (no) 1992-04-15
US4891367A (en) 1990-01-02
KR880012634A (ko) 1988-11-28
CN1024279C (zh) 1994-04-20
EP0291717A1 (en) 1988-11-23
AU1472088A (en) 1988-10-27
NO881745L (no) 1988-10-24
DE3872938T2 (de) 1993-01-07
DK167766B1 (da) 1993-12-13
EP0291717B1 (en) 1992-07-22
DK217488D0 (da) 1988-04-21
ZA882715B (en) 1988-10-17
HU198508B (en) 1989-10-30
JPS63284194A (ja) 1988-11-21
AU605575B2 (en) 1991-01-17
FI881878L (fi) 1988-10-23
NO881745D0 (no) 1988-04-21
PH23863A (en) 1989-11-23
CA1309088C (en) 1992-10-20
FI881878A0 (fi) 1988-04-21
IL86140A (en) 1993-02-21
DE3872938D1 (de) 1992-08-27
GR3005370T3 (enExample) 1993-05-24
ATE78487T1 (de) 1992-08-15
FI87791C (fi) 1993-02-25
PT87293B (pt) 1992-08-31
FI87791B (fi) 1992-11-13
HUT47305A (en) 1989-02-28
IL86140A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
EP0413269B1 (en) 4-substituted 17-beta-(cyclopropyloxy)androst-5-EN-3-beta-OL and related compounds useful as C17-20 lyase inhibitors
EP0133995B1 (en) Steroids and therapeutic compositions containing same
KR960015036B1 (ko) C_17-20 리아제 억제제로서 유용한 17β-(사이클로 프로필옥시) 안드로스트-5-엔-3β-올 및 이와 관련된 화합물
CZ297316B6 (cs) Steroidní slouceniny a farmaceutický prostredek sjejich obsahem
EP0413270B1 (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as C17-20 lyase inhibitors
JPS6013796A (ja) １−アルキル−アンドロスタ−１，４−ジエン−３，１７−ジオン、その製法及び該化合物を含有するエストロゲン生合成を阻害する製薬的製剤
CA1314871C (en) Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agents
JP2750621B2 (ja) ３β，１７β―ヒドロキシ―置換ステロイド及び関連するステロイド化合物類
JPS6355488B2 (enExample)
JP2566574B2 (ja) 抗癌および抗肥満剤として有用なステロイド
US4052421A (en) 13-ethinyl-steroids and processes for their manufacture
CA1069117A (en) PROCESS FOR THE PREPARATION OF 11.beta.-HYDROXY-18-ALKYL-ESTRANE COMPOUNDS
HU184974B (en) Process for producing 3-keto-steroide derivatives
GB2185257A (en) 10 beta (-Alkynyl-4,9(11)-estradiene derivatives and process for their preparation
GB2185258A (en) 10 beta -Halo-alkynyl estrene derivatives and process for their preparation
WO1994010190A1 (en) 6,7α-DIFLUOROMETHYLENANDROSTA-1,4-DIEN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
IE73240B1 (en) Steroids and therapeutic compositions containing same

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20021017

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20031025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20031025

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000